Scholars Central

Conference abstractPublished 18 Jul 2018

New erecting perspectives for phosphodiesterase 5 inhibitors

Authors: Ashraf H Abadi

German University in Cairo, Egypt

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Phosphodiesterase 5 inhibitors are mainly indicated for the treatment of erectile dysfunction. Currently approved compounds differ mainly in their pharmacokinetics profile and propensity to induce side effects caused due to cross-inhibition of other PDEs. The mechanism of action of PDE5 inhibitors includes elevating the levels of the universal messenger cGMP in different cells, thus several potential uses and indications are currently emerging including, treatment of pulmonary arterial hypertension, congestive heart failure, raynaud’s disease, benign prostatic hyperplasia, enhancement of cognitive functions, enhancement of hearing, as well as prevention and treatment of different types of cancer, particularly the colorectal one. From discovery perspective, a newly emerging class is GAF domain rather than catalytic domain is also emerging. This class shows favorable properties better than classic inhibitors.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutical Care & Health Systems
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Ashraf H Abadi”